Stoeva, V.; Petrova, G.; Mitov, K.; Tachkov, K. Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib. Pharmaceuticals2023, 16, 976.
Stoeva, V.; Petrova, G.; Mitov, K.; Tachkov, K. Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib. Pharmaceuticals 2023, 16, 976.
Stoeva, V.; Petrova, G.; Mitov, K.; Tachkov, K. Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib. Pharmaceuticals2023, 16, 976.
Stoeva, V.; Petrova, G.; Mitov, K.; Tachkov, K. Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib. Pharmaceuticals 2023, 16, 976.
Abstract
We aimed to explore symptoms severity and adherence to therapy for patients with myelofibrosis treated with ruxolitinib in Bulgaria.
It is a prospective, non-interventional study performed at the Specialized hospital for active treatment of hematological diseases in Sofia during 2022 - 2023. Date of diagnosis, demographic characteristics, clinical indicators, ruxolitinib dose, and other data points were collected. Clinical indicators were assessed at baseline, in the middle and at the end of observation. Severity of symptoms was measured with MPN-SAF TSS and adherence to therapy with the Morisky 4 questionnaire 6 times during the observation.
The mean age of diagnosis was 58.5 years, with the average duration of disease of 3 years. Pa-tients’ laboratory results were within physiological ranges, with spleen size experiencing a con-stant decrease. The average value for the severity of the symptoms per MPN-SAF TSS results decreased significantly, indicating better disease control. The average adherence to therapy did not change and remained high at around 9 points, except for one patient.
In conclusion the treatment of myelofibrosis patients with ruxolitinib decreased symptoms se-verity and spleen size. Patients were adherent to the therapy over the observed period but as treatment duration increases the risk of adherence decreasing.
Keywords
myelofibrosis; ruxolitinib; severity of symptoms; adherence to therapy
Subject
Medicine and Pharmacology, Hematology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
